Trial Results Demonstrate Significant Overall Survival With Zanidatamab in Adenocarcinoma
January 25th 2023In patients with HER2-expressing metastatic gastroesophageal adenocarcinoma administered zanidatamab, the median duration of response was 20.4 months, with a median progression-free survival of 12.5 months.
Read More